SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT ...Middle East

Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour DUBLIN and OXFORD, England, April 22, 2024 /PRNewswire/ -- SynOx Therapeutics Limited...

Hence then, the article about synox therapeutics announces 75m series b round to fund phase 3 trial of potential best in class treatment for tgct was published today ( Monday 22/04/2024 - 10:32 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT )

Also on site :

• James Patterson Thriller Among 'Best Honeymoon Books' List on Goodreads
• Los niños ya representan la mitad de las pandillas en Haití. Están a punto de enfrentarse a una nueva fuerza extranjera
• NYT ‘Connections’ Hints, Clues and Answers Today, Wednesday, April 8, 2026